Help
Technical Support Information – Desktop Computers
In order to view the webcast, you must have a currently supported HTML5 compliant web browser with standards-based media playback support on supported versions of the Windows and Macintosh operating systems.
Video webcasts require that you have a broadband Internet connection with at least 600kbps of download connectivity. If you are having difficulty with playback of a video webcast, for example playback is buffering frequently, please check your internet connection. Downloadable audio-only MP3 files are available for each session.
If you are still having trouble viewing the webcasts, please carefully review the detailed System Requirements and Troubleshooting Steps webpage.
Using the Capital Reach Media Player
For each session, there may be two different versions of the media player. Some sessions may include video of the presenter.
- Slide video – video of the speaker's slide presentation is the default stream displayed in the player. This option displays all speaker mouse movements and videos included in presentations.
- Audio and slides – audio of the speaker's presentation is the default stream in the player. Static slide images in the slide presentations are synchronized to the audio stream.
Navigating the Presentation Webcast
The player offers several tools to navigate the presentation:
- "Browse Slides" icon – select the browse slides icon to navigate to any slide in the presentation by selecting the slide thumbnail image.
Player Tools
- "Speaker Information" icon – if available, displays information about the speakers and presentations in the session.
- "Download Media" icon – select this button to download an audio-only file of the session.
-
Playback Controls
- Play/Pause button – select this button to play or pause the default media stream of the player.
- Stop button – select this button to stop the default media stream of the player.
Mobile Device Support
Presentation playback is available on supported versions of Apple iOS devices (Apple iPad and iPhone) and Android devices with an enabled Internet connection and a currently supported web browser with standards based media playback support. Users of these devices can stream sessions to their mobile device. Users have the option to stream either slide presentation video or audio-only from the session. Please note that some advanced interactivity features of the desktop player may not be supported on the Apple iOS mobile devices.
Speaker Info
Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline
Charles A Sklar, MD
Memorial Sloan Kettering Cancer Center, New York, NY
Dr. Charles Sklar is currently the Director of the Long-Term Follow-Up Program, an Attending Pediatrician and full Member, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, and Professor of Pediatrics, Weill Cornell College of Medicine, New York City. He has a long-standing research interest in the endocrine, metabolic and reproductive complications of cancer therapy in survivors of childhood cancer. He is a founding investigator and member of the Executive Committee for the Childhood Cancer Survivor Study, a landmark study funded by the National Cancer Institute that is tracking some 24,000 survivors of childhood cancer treated in North America. Dr. Sklar has authored more than 200 peer reviewed articles, chapters, and reviews.
Hanneke M van Santen, MD, PhD
Wilhelmina Children's Hospital, Utrecht, Netherlands
Dr. HM van Santen , pediatric endocrinologist, is highly specialized in endocrine consequences of childhood cancer treatment. She moved her career in 2013 to Utrecht, the Netherlands to support the Máxima initiative and to coordinate the endocrine care for children with cancer in the Princess Máxima Center. She has co-authored > 40 publications on the endocrine effects of childhood cancer treatment, of which 27 as first or last author. She is a PI in the research program of Child Health, WKZ, UMCU and collaborates closely together with the Máxima (Prof dr. MM van den Heuvel-Eibrink, medical director of the LATE Effects group in the Máxima , Prof. dr. LC. Kremer, PI of the Dutch Childhood Oncology Group LATER). She is a team-member of the pediatric neuro-oncology group of the Máxima (head: Prof.dr. E Hoving). Internationally, she collaborates closely with the endocrine and late effects department of the St Jude's Hospital (Dr W Chemaitilly, Dr M Hudson). Her research program focusses on the endocrine effects of childhood cancer treatment, with special interest for the thyroid and pituitary gland, aiming to preserve an intact endocrine system in children with cancer enabling normal growth and development of the child during and after childhood cancer treatment. She is chair of the Late Effects of Childhood Cancer International Guideline Harmonization Groups (IGHG) for thyroid and hypothalamic-pituitary disorders, and member of the IGHG working groups for male and female gonadal toxicity and preservation of fertility and metabolic syndrome. She is chair of the Dutch Guideline for Thyroid cancer in children and the coordinator of the ERN Thyroid Tumors in Utrecht. She is member of the SKION craniopharyngioma working group, the SIOP supportive care group, the SIOP low grade glioma working group, the national consortium for Late effects of treatment for childhood thyroid carcinoma, the consortium of the Dexadagen-2 study, the Dutch Growth Hormone Advisory board and has a consultative function for the “Cyberpoli” for thyroid diseases and craniopharyngioma.
Wassim Chemaitilly, MD
St. Jude Children's Research Hospital, Memphis, TN
Dr. Wassim Chemaitilly is a pediatric endocrinologist with established interest in the long term adverse effects of cancer and brain tumor treatments on the endocrine system. Dr. Chemaitilly obtained his Medical Doctorate degree and Pediatric Medicine diploma at the Université René Descartes - Necker Enfants Malades in Paris, France before completing a Pediatric Endocrinology fellowship at New York Presbyterian Hospital - Weill Cornell Medical College in New York City in 2006. Dr. Chemaitilly currently serves as the director of the Endocrinology Division at St. Jude Children's Research Hospital in Memphis, Tennessee and has a joint faculty appointment with the institution's Department of Epidemiology and Cancer Control where he conducts most of his clinical research. He has contributed to more than 70 peer reviewed articles and book chapters pertaining to various topics in pediatric endocrinology, with a focus on the endocrine late-effects of childhood cancer.
Zoltan Antal, MD
Weill Cornell Medical College, New York, NY
Dr. Antal received his medical degree from St George's University School of Medicine, completed residency at SUNY Downstate Kings County Hospital, and completed a fellowship in Pediatric Endocrinology at the Children's Hospital at Montefiore. He is currently an Associate Professor of Clinical Pediatrics and Chief of the Division of Pediatric Endocrinology at Weill Cornel Medicine. He is also an attending physician at New York Presbyterian Hospital as well as at Memorial Sloan Kettering Cancer Center. Dr. Antal's clinical and research interests focus on the endocrinopathies seen following treatment for childhood cancer. Specifically, he is interested in evaluating growth, pubertal development, and testicular function in childhood cancer survivors. He is a member of the pediatric long-term follow up survivorship team at Memorial Sloan Kettering Cancer Center, and was part of a committee which recently published endocrine society guidelines for evaluating and treating growth and pituitary function following treatment for childhood cancer. He is also a co-chair of the Children's Oncology Group endocrine task force testicular silo which is responsible for aiding in the update and development of the Children's Oncology Group Survivorship Guidelines.
Laurie E Cohen, MD
Boston Children's Hospital, Boston, MA
Download Media
Index
Browse Slides
Media Quality
Media quality is automatically adjusted based on the speed of your internet connection. If you would prefer to control the quality explicitly, please choose from the options above.